Filter by tags: Clinical trial Lutetium Clear all tag filters
3 news articles found
Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.
Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.
According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.
- Source: Nucnet
- Date: Friday, 14 April 2023
- Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023
The Australian Nuclear Science and Technology Organisation (Ansto) said a new radioactive variation of the element scandium, scandium-47, had been produced in the OPAL reactor.
- Source: NEI Magazine
- Date: Tuesday, 24 March 2020
- Original article: neimagazine.com/news/newsansto-develops-produces-scandium-47-for-the-first-time-7833921
A new radioactive version of the element scandium has been produced in Australia's OPAL reactor for the first time. Scandium-47 has the potential for theranostic use, that is, both as a therapeutic drug and a diagnostic agent, and has similar properties to lutetium-177, which is already being used in clinical trials.
- Source: World Nuclear News
- Date: Friday, 20 March 2020
- Original article: world-nuclear-news.org/Articles/Australia-produces-first-batch-of-medical-isotope